The MCED Inflection Point: What Galleri's FDA Panel Backing Means for Cancer Screening
Dr. Dereck Mush, MD, MBA
BostonGene
Performs integrated genomic and transcriptomic profiling of patient tumors and microenvironments.
What they do
BostonGene provides molecular profiling and advanced bioinformatics analysis for oncology patients. Its platform analyzes the genomic and immune microenvironment profile of tumors, delivering comprehensive reports that clinicians use to select personalized chemotherapy, immunotherapy, and targeted therapies.
The record
- Vertical
- Oncology
- Sub-segment
- Cancer screening and diagnostics
- Product type
- Diagnostics
- Stage
- Series B
- Headquarters
- Boston, United States
- Region
- North America
- Founded
- 2015
- Total funding
- $250M raised
Notable investors: NEC Corporation.
Also in Oncology
Related on The Signal
Dr. Dereck Mush, MD, MBA
The barbershop health screening model is expanding well beyond blood pressure
Dr. Dereck Mush, MD, MBA
Screening Programs Are Rebuilding Around Reminder Systems That Actually Reach People
Dr. Dereck Mush, MD, MBA
PATHFINDER 2 Results: What the Galleri Multi-Cancer Blood Test Actually Found
Dr. Dereck Mush, MD, MBA